Quick Answer
LIGAND PHARMACEUTICALS INC reported Cash And Cash Equivalents At Carrying Value of $174.93 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +141.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), LIGAND PHARMACEUTICALS INC's Cash And Cash Equivalents At Carrying Value has grown by 508.4%.
- Historical annual values: Fiscal year 2025: $174.93 million | Fiscal year 2024: $72.31 million | Fiscal year 2023: $22.95 million | Fiscal year 2022: $45.01 million | Fiscal year 2021: $19.52 million | Fiscal year 2020: $47.62 million | Fiscal year 2019: $71.54 million | Fiscal year 2018: $117.16 million | Fiscal year 2017: $20.62 million | Fiscal year 2016: $18.75 million | Fiscal year 2015: $97.43 million | Fiscal year 2014: $160.20 million | Fiscal year 2013: $11.64 million | Fiscal year 2012: $12.38 million | Fiscal year 2011: $7.04 million | Fiscal year 2010: $3.35 million | Fiscal year 2009: $16.03 million | Fiscal year 2008: $28.75 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: